HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease.
highlifemedical.comParis, FranceHealthtechFounded 2010
9 sources · checked 2 times, last 44d ago
The company release states "$90+ Million (€80 Million)"; the later article says "over $90 million (€80 million)," so the company release's wording is used.
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The headline calls it “Round B,” while the release body calls it “Series B”; the body’s Series B label is used.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source does not state a conventional stage such as seed or Series A.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round | $90M | 2026-09-22 | Andera Partners, Mérieux Equity Partners, Sofinnova Partners, Supernova Invest | No recent discussion |
9 sources · checked 2 times, last 44d ago [ VERIFIED ] read against 4 of 9 sources
The company release states "$90+ Million (€80 Million)"; the later article says "over $90 million (€80 million)," so the company release's wording is used. | ||||
2 people on 7 outlets
Found on X with Firecrawl search
HighLife builds a transfemoral transcatheter mitral-valve replacement system for adults with symptomatic moderate-to-severe or severe mitral regurgitation who are not suitable for surgery or transcatheter repair.
HighLife is targeting adults with severe mitral regurgitation who may be unsuitable for surgery or transcatheter edge-to-edge repair, using a transfemoral, dual-component valve-in-ring system intended to reduce leakage and avoid a surgical approach. Its 2026 CE approvals and $90+ million financing are funding a limited European commercial rollout and a U.S. pivotal study for a patient population the company describes as having limited therapeutic alternatives.
Checked against 11 sources on Sep 27
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $36.5M € 32 million | 2019-01-17 | Andera Partners, U.S. Venture Partners | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources
The headline calls it “Round B,” while the release body calls it “Series B”; the body’s Series B label is used. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: highlifemedical.com, eu-startups.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 of 2 sources·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $14.3M €12.3 million | 2017-10-30 | Sofinnova Partners | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The source does not state a conventional stage such as seed or Series A. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: highlifemedical.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||